218 related articles for article (PubMed ID: 34127031)
21. Reappraisal of TLE-1 immunohistochemical staining and molecular detection of SS18-SSX fusion transcripts for synovial sarcoma.
Chuang HC; Hsu SC; Huang CG; Hsueh S; Ng KF; Chen TC
Pathol Int; 2013 Dec; 63(12):573-80. PubMed ID: 24422953
[TBL] [Abstract][Full Text] [Related]
22. Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.
Zöllner SK; Rössig C; Toretsky JA
Cancer Metastasis Rev; 2015 Sep; 34(3):417-28. PubMed ID: 26277104
[TBL] [Abstract][Full Text] [Related]
23. Histology and grading are important prognostic factors in synovial sarcoma.
Bianchi G; Sambri A; Righi A; Dei Tos AP; Picci P; Donati D
Eur J Surg Oncol; 2017 Sep; 43(9):1733-1739. PubMed ID: 28579008
[TBL] [Abstract][Full Text] [Related]
24. SS18-SSX Expression in a Contemporary Cohort of Primary Renal Synovial Sarcoma: A Multi-Institutional Experience of Fourteen Patients.
Challa B; Mohanty SK; Jha S; Sampat NY; Sardana R; Lobo A; Sharma S; Arora S; Rath D; Munjal G; Pattnaik N; Jain D; Jain E; Dewan A; Dixit M; Malik V; Shinde S; Balzer BL; Parwani A
Int J Surg Pathol; 2023 Oct; 31(7):1232-1243. PubMed ID: 36591871
[TBL] [Abstract][Full Text] [Related]
25. Immunoreactivity of a Monoclonal Antibody to SS18-SSX Fusion Gene Product in Formalin-fixed Paraffin-embedded Synovial Sarcoma Tissue Section.
Saigo C; Kito Y; Takeuchi T
Appl Immunohistochem Mol Morphol; 2018 Mar; 26(3):206-211. PubMed ID: 27362474
[TBL] [Abstract][Full Text] [Related]
26. Primary Synovial Sarcoma of the Bone: A Case Report and Literature Review.
Ichikawa J; Kawasaki T; Imada H; Kanno S; Ookita G; Taniguchi N; Ashizawa T; Tatsuno R; Jyubashi T; Haro H
Anticancer Res; 2023 Sep; 43(9):4241-4247. PubMed ID: 37648290
[TBL] [Abstract][Full Text] [Related]
27. Synovial Sarcoma of the Gastrointestinal Tract.
Ortiz Requena D; Longacre TA; Rosenberg AE; Velez Torres JM; Yanchenko N; Garcia-Buitrago MT; Voltaggio L; Montgomery EA
Mod Pathol; 2024 Jan; 37(1):100383. PubMed ID: 37972927
[TBL] [Abstract][Full Text] [Related]
28. Primary intrathoracic synovial sarcoma: a clinicopathologic study of 40 t(X;18)-positive cases from the French Sarcoma Group and the Mesopath Group.
Bégueret H; Galateau-Salle F; Guillou L; Chetaille B; Brambilla E; Vignaud JM; Terrier P; Groussard O; Coindre JM
Am J Surg Pathol; 2005 Mar; 29(3):339-46. PubMed ID: 15725802
[TBL] [Abstract][Full Text] [Related]
29. Proteomic signatures corresponding to the SS18/SSX fusion gene in synovial sarcoma.
Ishii M; Suehara Y; Sano K; Kohsaka S; Hayashi T; Kazuno S; Akaike K; Mukaihara K; Kim Y; Okubo T; Takamochi K; Takahashi F; Kaneko K; Saito T
Oncotarget; 2018 Dec; 9(101):37509-37519. PubMed ID: 30680066
[TBL] [Abstract][Full Text] [Related]
30. Release of circulating tumor cells and cell-free nucleic acids is an infrequent event in synovial sarcoma: liquid biopsy analysis of 15 patients diagnosed with synovial sarcoma.
Mihály D; Nagy N; Papp G; Pápai Z; Sápi Z
Diagn Pathol; 2018 Oct; 13(1):81. PubMed ID: 30326929
[TBL] [Abstract][Full Text] [Related]
31. Primary pleuropulmonary and mediastinal synovial sarcoma: a clinicopathologic and molecular study of 26 genetically confirmed cases in the largest institution of southwest China.
Lan T; Chen H; Xiong B; Zhou T; Peng R; Chen M; Ye F; Yao J; He X; Wang Y; Zhang H
Diagn Pathol; 2016 Jul; 11(1):62. PubMed ID: 27401493
[TBL] [Abstract][Full Text] [Related]
32. The diagnostic value of SYT-SSX detected by reverse transcriptase-polymerase chain reaction (RT-PCR) and fluorescence in situ hybridization (FISH) for synovial sarcoma: a review and prospective study of 255 cases.
Sun B; Sun Y; Wang J; Zhao X; Zhang S; Liu Y; Li X; Feng Y; Zhou H; Hao X
Cancer Sci; 2008 Jul; 99(7):1355-61. PubMed ID: 18460022
[TBL] [Abstract][Full Text] [Related]
33. Primary cardiac synovial sarcoma: a clinicopathological, immunohistochemical, and molecular genetics study of five clinical cases.
Teng F; Chen D; Li Y; Fang W; Yang S; Shang J; Liu G; Cui Y; Zhao Y; Lian G
Cardiovasc Pathol; 2021; 50():107286. PubMed ID: 32947039
[TBL] [Abstract][Full Text] [Related]
34. The SS18-SSX Antibody Has Perfect Specificity for the SS18-SSX Fusion Protein: A Validation Study of 609 Neoplasms Including 2 Unclassified Tumors With SS18-Non-SSX Fusions.
Perret R; Velasco V; Le Guellec S; Coindre JM; Le Loarer F
Am J Surg Pathol; 2021 Apr; 45(4):582-584. PubMed ID: 33234877
[No Abstract] [Full Text] [Related]
35. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
[TBL] [Abstract][Full Text] [Related]
36. The C terminus of the synovial sarcoma-associated SSX proteins interacts with the LIM homeobox protein LHX4.
de Bruijn DR; van Dijk AH; Willemse MP; van Kessel AG
Oncogene; 2008 Jan; 27(5):653-62. PubMed ID: 17667940
[TBL] [Abstract][Full Text] [Related]
37. Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma.
Wakamatsu T; Naka N; Sasagawa S; Tanaka T; Takenaka S; Araki N; Ueda T; Nishizawa Y; Yoshikawa H; Itoh K
Cancer Sci; 2014 Sep; 105(9):1124-34. PubMed ID: 24975049
[TBL] [Abstract][Full Text] [Related]
38. Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma.
Carmody Soni EE; Schlottman S; Erkizan HV; Uren A; Toretsky JA
Clin Orthop Relat Res; 2014 Mar; 472(3):874-82. PubMed ID: 23716114
[TBL] [Abstract][Full Text] [Related]
39. An SS18::NEDD4 cutaneous spindled and epithelioid sarcoma: An hitherto unclassified cutaneous sarcoma, resembling epithelioid sarcoma with aggressive clinical behavior.
Patton A; Oghumu S; Iwenofu OH
Genes Chromosomes Cancer; 2022 Oct; 61(10):635-640. PubMed ID: 35639915
[TBL] [Abstract][Full Text] [Related]
40. SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier.
Tamaki S; Fukuta M; Sekiguchi K; Jin Y; Nagata S; Hayakawa K; Hineno S; Okamoto T; Watanabe M; Woltjen K; Ikeya M; Kato T; Toguchida J
PLoS One; 2015; 10(11):e0142991. PubMed ID: 26571495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
